Mineralys Therapeutics Announces Q3 2024 Results and Updates [Yahoo! Finance]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: Yahoo! Finance
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on developing treatments for hypertension, chronic kidney disease, and related conditions driven by dysregulated aldosterone. In its third-quarter 2024 earnings report, Mineralys Therapeutics highlighted key advancements in its clinical trials and financial performance. Notably, the company completed enrollment for two pivotal trials ahead of schedule and anticipates delivering topline data in the first half of 2025. Financially, Mineralys reported a net loss of $56.3 million for the third quarter of 2024, compared to $22.8 million in the same period last year. This increase in net loss primarily stems from a significant rise in research and development expenses, which rose to $54 million due to the progression of their lorundrostat pivotal program. The company's cash reserves stand at $263.6 million, which are expected to fund operations into 2026. Strategically, Mineralys is making significant
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Mineralys Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024GlobeNewswire
MLYS
Earnings
- 11/11/24 - Miss
MLYS
Sec Filings
- 11/13/24 - Form SC
- 11/13/24 - Form SC
- 11/13/24 - Form SC
- MLYS's page on the SEC website